Quantcast
Home > Quotes > TTNP

Titan Pharmaceuticals, Inc. Common Stock (TTNP) Quote & Summary Data

TTNP 
$0.7564
*  
0.0266
3.4%
Get TTNP Alerts
*Delayed - data as of May 21, 2018  -  Find a broker to begin trading TTNP now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
5
Today's High / Low
$ 0.8372 / $ 0.708
Share Volume
154,891
50 Day Avg. Daily Volume
127,985
Previous Close
$ 0.783
52 Week High / Low
$ 2.85 / $ 0.60
Market Cap
16,038,512
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.22

Intraday Chart

Shares Traded

Share Volume:
154,891
50 Day Avg. Daily Volume:
127,985

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.66

Trading Range

The current last sale of $0.7564 is 26.07% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.8372 $ 2.85
 Low: $ 0.708 $ 0.60

Company Description (as filed with the SEC)

We are a pharmaceutical company developing proprietary therapeutics for the treatment of serious medical disorders. Our product development programs utilize our proprietary long-term drug delivery platform, ProNeura(TM), and focus primarily on innovative treatments for select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. Probuphine┬«, our first product candidate based on the ProNeura platform, was approved by the FDA in May 2016 for the maintenance treatment of opioid dependence in patients who are stable on low to moderate doses of daily sublingual buprenorphine treatment. We licensed development and commercialization rights of Probuphine for the U.S. and Canadian markets to Braeburn Pharmaceuticals, Inc., or Braeburn. In the first quarter of 2017, Braeburn commenced a full commercial launch of the product.  ... More ...  

Risk Grade

Where does TTNP fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.76
Open Date:
May 21, 2018
Close Price:
$ 0.783
Close Date:
May 21, 2018

Consensus Recommendation

Analyst Info